Wei Ya Zhen Sheng Wu Ji Shu

V-Zhen Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative RNA interference (RNAi) therapeutics. Established in 2022, the company focuses on addressing significant unmet medical needs in cardiovascular, metabolic, and liver-related diseases. Through a strategic partnership with Arrowhead Pharmaceuticals, V-Zhen holds exclusive rights to develop and commercialize several late-stage siRNA candidates in the Greater China region. Its lead programs, VZ-001 and VZ-002, target key genetic drivers of lipid metabolism and are currently undergoing advanced clinical trials to treat severe dyslipidemia and high cardiovascular risk.